SunTrust Banks, Inc. restated their buy rating on shares of Amedisys Inc (NASDAQ:AMED) in a research note issued to investors on Monday morning. SunTrust Banks, Inc. currently has a $60.00 target price on the health services provider’s stock.

Several other brokerages have also weighed in on AMED. Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $60.00 target price on shares of Amedisys in a research note on Friday, September 15th. BidaskClub lowered shares of Amedisys from a hold rating to a sell rating in a research note on Saturday, August 5th. Bank of America Corporation initiated coverage on shares of Amedisys in a research note on Monday, August 21st. They set a neutral rating and a $55.00 target price for the company. Robert W. Baird reaffirmed a hold rating and set a $50.00 target price on shares of Amedisys in a research note on Wednesday, October 4th. Finally, Mizuho lowered shares of Amedisys from a buy rating to a neutral rating and set a $50.00 target price for the company. in a research note on Wednesday, July 26th. Seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $56.20.

Shares of Amedisys (NASDAQ:AMED) opened at 48.63 on Monday. The stock has a 50 day moving average of $51.93 and a 200 day moving average of $55.20. Amedisys has a 12-month low of $34.58 and a 12-month high of $65.91. The company has a market cap of $1.65 billion, a price-to-earnings ratio of 41.56 and a beta of 0.87.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.42 earnings per share. Equities research analysts predict that Amedisys will post $2.21 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.dailypolitical.com/2017/10/12/amedisys-inc-amed-earns-buy-rating-from-suntrust-banks-inc.html.

In other Amedisys news, Director Bruce D. Perkins purchased 2,000 shares of Amedisys stock in a transaction dated Thursday, August 3rd. The shares were acquired at an average price of $46.60 per share, with a total value of $93,200.00. Following the completion of the transaction, the director now owns 15,825 shares of the company’s stock, valued at $737,445. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider David B. Pearce sold 1,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the insider now directly owns 10,488 shares in the company, valued at approximately $524,400. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Amedisys during the second quarter worth about $591,000. Piedmont Investment Advisors LLC acquired a new stake in shares of Amedisys during the second quarter worth about $380,000. Castleark Management LLC acquired a new stake in shares of Amedisys during the second quarter worth about $3,674,000. The Manufacturers Life Insurance Company lifted its position in shares of Amedisys by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 22,348 shares of the health services provider’s stock worth $1,404,000 after purchasing an additional 410 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Amedisys by 3.9% during the second quarter. State Street Corp now owns 723,786 shares of the health services provider’s stock worth $45,461,000 after purchasing an additional 26,888 shares in the last quarter. 96.55% of the stock is currently owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.